Last 48 quarters of trend data · Consumer Defensive · Household & Personal Products
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Nu Skin Enterprises, Inc.'s quarterly P/E stands at 48.9x, up 5668.5% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has compressed 77.6% YoY to 6.0x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 1.58 | 48.92 | 8.29 | 8.96 | 4.65 | 0.85 | — | 10.84 | — | — | 32.37 | — | 15.37 |
| — | +5668.5% | — | -17.3% | — | — | — | — | — | — | +253.1% | — | -4.9% | |
| P/S Ratio | 0.16 | 0.28 | 0.32 | 0.42 | 0.26 | 0.25 | 0.19 | 0.21 | 0.30 | 0.41 | 0.49 | 0.53 | 0.83 |
| — | +11.9% | +68.7% | +97.6% | -14.1% | -38.9% | -60.9% | -59.8% | -64.2% | -59.8% | -51.1% | -31.9% | -15.4% | |
| P/B Ratio | 0.31 | 0.45 | 0.60 | 0.77 | 0.50 | 0.48 | 0.53 | 0.52 | 0.76 | 0.85 | 1.17 | 1.29 | 1.86 |
| — | -6.5% | +13.4% | +47.9% | -34.2% | -42.7% | -55.0% | -59.7% | -59.0% | -61.6% | -50.0% | -35.4% | -20.7% | |
| P/FCF | 5.30 | — | 20.48 | 8.73 | 2.76 | — | 6.49 | 4.01 | 3.04 | — | 7.11 | 6.76 | 20.01 |
| — | — | +215.8% | +117.5% | -9.1% | — | -8.8% | -40.6% | -84.8% | — | -84.1% | -95.2% | +34.2% | |
| EV / EBITDA | 2.58 | 6.02 | 4.19 | 4.84 | 2.52 | 26.86 | — | 4.50 | — | 9.45 | 9.84 | — | 8.43 |
| — | -77.6% | — | +7.4% | — | +184.4% | — | — | — | -44.2% | -23.0% | — | +0.2% | |
| EV / EBIT | 4.06 | 18.70 | 6.52 | 8.11 | 3.69 | 0.84 | — | 8.09 | — | 30.56 | 35.17 | — | 11.73 |
| — | +2131.1% | — | +0.2% | — | -97.3% | — | — | — | +6.4% | +173.8% | — | +2.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Nu Skin Enterprises, Inc.'s operating margin was 1.8% in Q1 2026, down 4.4 pp QoQ and up 4.5 pp YoY. The trailing four-quarter average of 5.5% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.4% | 66.9% | 70.7% | 70.5% | 68.8% | 67.8% | 62.7% | 70.1% | 70.0% | 70.5% | 72.1% | 58.6% | 72.9% |
| — | -1.3% | +12.9% | +0.6% | -1.6% | -3.8% | -13.1% | +19.6% | -4.0% | -2.5% | +0.6% | -13.5% | -0.9% | |
| Operating Margin | 6.1% | 1.8% | 6.3% | 5.9% | 8.0% | -2.7% | -11.9% | 4.2% | -28.6% | 2.1% | 3.3% | -5.3% | 8.5% |
| — | +167.3% | +152.7% | +40.2% | +127.9% | -228.5% | -462.4% | +180.2% | -436.5% | -36.6% | -37.5% | -40.2% | -7.6% | |
| Net Margin | 10.8% | 0.6% | 3.9% | 4.7% | 5.5% | 29.5% | -8.1% | 1.9% | -26.9% | -0.1% | 1.5% | -7.4% | 5.4% |
| — | -98.1% | +148.3% | +143.0% | +120.3% | +23199.0% | -643.7% | +126.0% | -601.0% | -105.4% | -86.4% | -56.9% | -12.0% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.0% | 0.2% | 1.8% | 2.2% | 2.7% | 15.3% | -5.3% | 1.2% | -15.8% | -0.1% | 0.9% | -4.3% | 3.0% |
| — | -98.5% | +134.0% | +80.5% | +117.3% | +23530.3% | -700.1% | +127.7% | -625.6% | -105.1% | -86.5% | -51.1% | -17.6% | |
| ROA | 11.1% | 0.1% | 1.0% | 1.2% | 1.5% | 7.5% | -2.4% | 0.5% | -7.1% | -0.0% | 0.4% | -2.0% | 1.4% |
| — | -98.2% | +143.3% | +127.3% | +121.0% | +25159.0% | -685.1% | +126.1% | -591.4% | -104.8% | -87.3% | -44.6% | -19.9% | |
| ROIC | 7.3% | 0.5% | 2.0% | 1.9% | 2.7% | -0.8% | -4.1% | 1.4% | -8.8% | 0.6% | 1.0% | -1.6% | 2.7% |
| — | +158.9% | +147.6% | +39.8% | +131.2% | -245.7% | -500.8% | +184.3% | -430.9% | -45.4% | -44.7% | -16.1% | -24.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Nu Skin Enterprises, Inc.'s Debt/EBITDA ratio is 15.2x, up from 10.1x last quarter — elevated, raising questions about debt serviceability.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.45 | 0.35 | 0.45 | 0.36 | 0.39 | 0.40 | 0.73 | 0.71 | 0.77 | 0.69 | 0.74 | 0.69 | 0.65 |
| — | -12.3% | -38.4% | -48.7% | -48.8% | -42.0% | -0.6% | +2.2% | +18.5% | +23.1% | +27.4% | +16.3% | +18.3% | |
| Debt / EBITDA | 2.54 | 15.25 | 10.07 | 8.64 | 7.09 | 69.88 | — | 14.12 | — | 20.45 | 18.23 | — | 9.76 |
| — | -78.2% | — | -38.8% | — | +241.8% | — | — | — | +35.4% | +61.2% | — | +32.3% | |
| Current Ratio | 2.08 | 2.03 | 2.08 | 2.15 | 2.01 | 2.02 | 1.82 | 1.93 | 2.12 | 2.09 | 2.13 | 1.62 | 1.78 |
| — | +0.9% | +14.4% | +11.9% | -5.1% | -3.6% | -14.9% | +19.2% | +19.1% | +0.8% | +0.9% | -24.1% | -22.5% | |
| Quick Ratio | 1.40 | 1.34 | 1.38 | 1.45 | 1.38 | 1.29 | 1.17 | 1.20 | 1.33 | 1.24 | 1.28 | 0.94 | 0.94 |
| — | +3.8% | +17.5% | +21.5% | +3.6% | +4.5% | -8.4% | +26.5% | +40.8% | +13.2% | +11.4% | -23.3% | -31.4% | |
| Interest Coverage | 6.52 | 1.38 | 5.82 | 4.86 | 11.85 | 42.00 | -8.86 | 3.05 | -18.59 | 1.15 | — | -4.57 | 7.43 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NUS stock.
Nu Skin Enterprises, Inc.'s current P/E is 1.6x. The average P/E over the last 4 quarters is 17.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Nu Skin Enterprises, Inc.'s current operating margin is 6.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nu Skin Enterprises, Inc.'s business trajectory between earnings reports.